Table 4 The recall rates of thirteen methods on four testing sets.
From: Heterogeneity-optimized method for predicting immune checkpoint blockade response
Pan-cancer | Melanoma | NSCLC | Other cancers | |
|---|---|---|---|---|
Our model | 56.70% | 49.74% | 53.78% | 66.70% |
RE16 | 38.91% | 33.30% | 31.47% | 35.78% |
RF11 | 30.10% | 42.22% | 25.74% | 30.28% |
TMB | 25.64% | 18.94% | 18.94% | 24.51% |
SVM | 17.83% | 28.73% | 32.00% | 31.04% |
MLR | 26.64% | 42.17% | 29.84% | 27.48% |
NB | 30.22% | 47.15% | 25.93% | 31.78% |
GBDT | 32.22% | 37.81% | 47.92% | 32.84% |
AdaBoost | 34.87% | 48.72% | 53.98% | 47.85% |
LightGBM | 37.89% | 35.84% | 48.78% | 53.27% |
ExtraTrees | 48.75% | 42.87% | 44.58% | 48.95% |
BPNN | 21.78% | 29.82% | 31.27% | 24.81% |
DNN | 25.37% | 25.74% | 42.71% | 54.71% |
